作为肉瘤切除的腹膜后单中心Castleman病的临床特征及预后：来自一家大型肉瘤中心的见解
Clinical features and outcomes of retroperitoneal unicentric Castleman disease resected as sarcomas: insights from a high-volume sarcoma center.
作者信息
Gao Haicheng, Li Wenjie, Zou Boyuan, Liu Shibo, Miao Chengli
机构信息
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China.
出版信息
Front Surg. 2024 Sep 5;11:1371968. doi: 10.3389/fsurg.2024.1371968. eCollection 2024.
BACKGROUND
Castleman disease (CD) is a rare lymphoproliferative disorder that can occur anywhere along the lymphatic pathway. Retroperitoneal unicentric Castleman disease (UCD) is an extremely rare manifestation. This study aims to explore the clinical features and surgical treatment of retroperitoneal UCD.
METHODS
We retrospectively reviewed patients who underwent retroperitoneal tumor surgery and were diagnosed with CD based on postoperative pathology before December 31, 2022. Data from these patients were collected and analyzed.
RESULTS
A total of 15 patients were included in the final analysis. All patients underwent radical resection under general anesthesia. Two out of 15 patients (13.3%) experienced serious complications but recovered well. There were no perioperative deaths. The median follow-up time was 78.5 months (range: 18-107.5 months), and no deaths or recurrences occurred during this period.
CONCLUSIONS
Surgical treatment for retroperitoneal UCD is safe. Patients with retroperitoneal UCD can achieve long-time survival through complete resection.
背景
卡斯特leman病（CD）是一种罕见的淋巴增殖性疾病，可发生于淋巴途径的任何部位。腹膜后单中心卡斯特leman病（UCD）是一种极为罕见的表现形式。本研究旨在探讨腹膜后UCD的临床特征及外科治疗方法。
方法
我们回顾性分析了2022年12月31日前接受腹膜后肿瘤手术且术后病理诊断为CD的患者。收集并分析这些患者的数据。
结果
最终纳入分析的患者共15例。所有患者均在全身麻醉下接受根治性切除术。15例患者中有2例（13.3%）出现严重并发症，但恢复良好。无围手术期死亡病例。中位随访时间为78.5个月（范围：18 - 107.5个月），在此期间无死亡或复发情况发生。
结论
腹膜后UCD的外科治疗是安全的。腹膜后UCD患者通过完整切除可实现长期生存。
Zotero 插件